Meclofenamic acid

Chemical compound
  • M01AG04 (WHO) M02AA18 (WHO)
Identifiers
  • 2-[(2,6-dichloro-3-methylphenyl)amino]benzoic acid
CAS Number
  • 644-62-2
PubChem CID
  • 4037
IUPHAR/BPS
  • 7219
DrugBank
  • DB00939
ChemSpider
  • 3897
UNII
  • 48I5LU4ZWD
KEGG
  • D02341
ChEBI
  • CHEBI:6710
ChEMBL
  • ChEMBL509 checkY
CompTox Dashboard (EPA)
  • DTXSID0048559 Edit this at Wikidata
ECHA InfoCard100.010.382 Edit this at WikidataChemical and physical dataFormulaC14H11Cl2NO2Molar mass296.15 g·mol−1

Meclofenamic acid (used as meclofenamate sodium, brand name Meclomen) is a drug used for joint, muscular pain, arthritis and dysmenorrhea.[1] It is a member of the anthranilic acid derivatives (or fenamate) class of nonsteroidal anti-inflammatory drugs (NSAIDs) and was approved by the US FDA in 1980.[2] Like other members of the class, it is a cyclooxygenase (COX) inhibitor, preventing the formation of prostaglandins.[3]

Scientists led by Claude Winder from Parke-Davis invented meclofenamate sodium in 1964, along with fellow members of the class, mefenamic acid in 1961 and flufenamic acid in 1963.[4]: 718 

Patents on the drug expired in 1985[5]: 295  and several generics were introduced in the US, but as of July 2015 only Mylan still sold it.[6][7]

It is not widely used in humans as it has a high rate (30-60%) rate of gastrointestinal side effects.[8]: 310 

Adverse effects

In October 2020, the U.S. Food and Drug Administration (FDA) required the drug label to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in unborn babies that result in low amniotic fluid.[9][10] They recommend avoiding NSAIDs in pregnant women at 20 weeks or later in pregnancy.[9][10]

Use in horses

Meclofenamic acid is sold under the trade name "Arquel" for use in horses, and is administered as an oral granule form at a dose of 2.2 mg/kg/day.[11] It has a relatively slow onset of action, taking 36–48 hours for full effect,[12] and is most useful for treatment of chronic musculoskeletal disease.[13] It has been found to be beneficial for the treatment of navicular syndrome, laminitis, and osteoarthritis,[12] in some cases having a more profound effect than the commonly used NSAID phenylbutazone.[14] However, due to cost, it is not routinely used in practice. Toxicity due to excessive dosage is similar to that of phenylbutazone, including depression, anorexia, weight loss, edema, diarrhea, oral ulceration, and decreased hematocrit.[14]

References

  1. ^ "meclofenamate, Meclomen: Drug Facts, Side Effects and Dosing". medicinenet.com.
  2. ^ FDA Meclomen page at FDA Page accessed July 3, 2015
  3. ^ "Mefenamic Acid". NIH LiverTox Database. June 23, 2015. PMID 31643176. Retrieved July 3, 2015.
  4. ^ Whitehouse M (2009). "Drugs to Treat Inflammation: A Historical Overview.". In Rahman A, et al. (eds.). Frontiers in Medicinal Chemistry. Vol. 4. Bentham Science Publishers. pp. 707–729. ISBN 978-1-60805-207-3.
  5. ^ United States. Congress. Office of Technology Assessment Pharmaceutical R & D: Costs, Risks & Rewards DIANE Publishing, 1993 ISBN 978-0-7881-0468-8
  6. ^ "Meclofenamate sodium ANDAs". U.S. Food and Drug Administration. Archived from the original on 4 June 2015. Retrieved 3 July 2015.
  7. ^ "Mylan label for meclofenamate sodium". Daily Med. U.S. Food and Drug Administration. October 2013. Retrieved 3 July 2015.
  8. ^ Aronson JK (2009). Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs. Elsevier. ISBN 978-0-08-093294-1.
  9. ^ a b "FDA Warns that Using a Type of Pain and Fever Medication in Second Half of Pregnancy Could Lead to Complications". U.S. Food and Drug Administration (FDA) (Press release). 15 October 2020. Retrieved 15 October 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  10. ^ a b "NSAIDs may cause rare kidney problems in unborn babies". U.S. Food and Drug Administration. 21 July 2017. Retrieved 15 October 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  11. ^ McIlwraith CW, Frisbie DD, Kawcak CE (2001). "Nonsteroidal Anti-Inflammatory Drugs". Proc. AAEP. 47: 182–187.
  12. ^ a b Cotter GH, Riley WF, Beck CC, Coppock RW (1973). "Arquel (Cl- 1583). A new nonsteroidal anti-inflammatory drug for horses". Proceedings. Am Assoc Equine Practnr. 19: 81–90.
  13. ^ Snow DH, Baxter P, Whiting B (June 1981). "The pharmacokinetics of meclofenamic acid in the horse". Journal of Veterinary Pharmacology and Therapeutics. 4 (2): 147–56. doi:10.1111/j.1365-2885.1981.tb00724.x. PMID 7349327.
  14. ^ a b Lees P, Higgins AJ (March 1985). "Clinical pharmacology and therapeutic uses of non-steroidal anti-inflammatory drugs in the horse". Equine Veterinary Journal. 17 (2): 83–96. doi:10.1111/j.2042-3306.1985.tb02056.x. PMID 3987667.
  • v
  • t
  • e
Non-steroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA)
pyrazolones /
pyrazolidinessalicylatesacetic acid derivatives
and related substancesoxicamspropionic acid
derivatives (profens)n-arylanthranilic
acids (fenamates)COX-2 inhibitors
(coxibs)otherNSAID
combinations
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; withdrawn drugs; veterinary use.
  • category
  • commons
  • portal
  • v
  • t
  • e
GABAA receptor positive modulators
Alcohols
Barbiturates
Benzodiazepines
Carbamates
Flavonoids
Imidazoles
Kava constituents
  • 10-Methoxyyangonin
  • 11-Methoxyyangonin
  • 11-Hydroxyyangonin
  • Desmethoxyyangonin
  • 11-Methoxy-12-hydroxydehydrokavain
  • 7,8-Dihydroyangonin
  • Kavain
  • 5-Hydroxykavain
  • 5,6-Dihydroyangonin
  • 7,8-Dihydrokavain
  • 5,6,7,8-Tetrahydroyangonin
  • 5,6-Dehydromethysticin
  • Methysticin
  • 7,8-Dihydromethysticin
  • Yangonin
Monoureides
Neuroactive steroids
Nonbenzodiazepines
Phenols
Piperidinediones
Pyrazolopyridines
Quinazolinones
Volatiles/gases
Others/unsorted
  • Unsorted benzodiazepine site positive modulators: α-Pinene
  • MRK-409 (MK-0343)
  • TCS-1105
  • TCS-1205
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators
  • v
  • t
  • e
Receptor
(ligands)
DP (D2)Tooltip Prostaglandin D2 receptor
DP1Tooltip Prostaglandin D2 receptor 1
DP2Tooltip Prostaglandin D2 receptor 2
EP (E2)Tooltip Prostaglandin E2 receptor
EP1Tooltip Prostaglandin EP1 receptor
  • Antagonists: AH-6809
  • ONO-8130
  • SC-19220
  • SC-51089
  • SC-51322
EP2Tooltip Prostaglandin EP2 receptor
  • Antagonists: AH-6809
  • PF-04418948
  • TG 4-155
EP3Tooltip Prostaglandin EP3 receptor
  • Antagonists: L-798106
EP4Tooltip Prostaglandin EP4 receptor
  • Antagonists: Grapiprant
  • GW-627368
  • L-161982
  • ONO-AE3-208
Unsorted
  • Agonists: 16,16-Dimethyl Prostaglandin E2
  • Aganepag
  • Carboprost
  • Evatanepag
  • Gemeprost
  • Nocloprost
  • Omidenepag
  • Prostaglandin F (dinoprost)
  • Simenepag
  • Taprenepag
FP (F)Tooltip Prostaglandin F receptor
IP (I2)Tooltip Prostacyclin receptor
  • Antagonists: RO1138452
TP (TXA2)Tooltip Thromboxane receptor
  • Agonists: Carbocyclic thromboxane A2
  • I-BOP
  • Thromboxane A2
  • U-46619
  • Vapiprost
Unsorted
  • Arbaprostil
  • Ataprost
  • Ciprostene
  • Clinprost
  • Cobiprostone
  • Delprostenate
  • Deprostil
  • Dimoxaprost
  • Doxaprost
  • Ecraprost
  • Eganoprost
  • Enisoprost
  • Eptaloprost
  • Esuberaprost
  • Etiproston
  • Fenprostalene
  • Flunoprost
  • Froxiprost
  • Lanproston
  • Limaprost
  • Luprostiol
  • Meteneprost
  • Mexiprostil
  • Naxaprostene
  • Nileprost
  • Nocloprost
  • Ornoprostil
  • Oxoprostol
  • Penprostene
  • Pimilprost
  • Piriprost
  • Posaraprost
  • Prostalene
  • Rioprostil
  • Rivenprost
  • Rosaprostol
  • Spiriprostil
  • Tiaprost
  • Tilsuprost
  • Tiprostanide
  • Trimoprostil
  • Viprostol
Enzyme
(inhibitors)
COX
(PTGS)
PGD2STooltip Prostaglandin D synthase
PGESTooltip Prostaglandin E synthase
HQL-79
PGFSTooltip Prostaglandin F synthase
PGI2STooltip Prostacyclin synthase
TXASTooltip Thromboxane A synthase
Others
See also
Receptor/signaling modulators
Leukotriene signaling modulators
  • v
  • t
  • e
Receptor
(ligands)
BLTTooltip Leukotriene B4 receptor
BLT1Tooltip Leukotriene B4 receptor 1
  • Agonists: 12-HETE
  • 20-Hydroxy-LTB4
  • Leukotriene B4
  • LY-255283
  • Antagonists: 20-Carboxy-LTB4
  • Amelubant
  • CGS-23131 (LY-223982)
  • CGS-25019C
  • CP-105696
  • CP-195543
  • Etalocib
  • LY-293111
  • Moxilubant
  • ONO-4057
  • RG-14893
  • RP-69698
  • SB-209247
  • SC-53228
  • Ticolubant
  • U-75302
  • ZK-158252
BLT2Tooltip Leukotriene B4 receptor 2
  • Antagonists: CP-195543
  • LY-255283
  • ZK-158252
CysLTTooltip Cysteinyl leukotriene receptor
CysLT1Tooltip Cysteinyl leukotriene receptor 1
  • Agonists: Leukotriene C4
  • Leukotriene D4
  • Leukotriene E4
  • Antagonists: Ablukast
  • BAYu9773
  • BAYu9916
  • BAYx7195
  • Cinalukast
  • FPL-55712
  • ICI-198615
  • Iralukast
  • LY-170680
  • Masilukast
  • MK-571
  • Montelukast
  • ONO-1078
  • Pobilukast
  • Pranlukast
  • Ritolukast
  • SKF-104353
  • SR-2640
  • Sulukast
  • Tipelukast
  • Tomelukast
  • Verlukast
  • Zafirlukast
  • ZD-3523
CysLT2Tooltip Cysteinyl leukotriene receptor 2
  • Agonists: Leukotriene C4
  • Leukotriene D4
  • Leukotriene E4
  • Antagonists: BAYu9773
  • BAYu9916
CysLTETooltip Cysteinyl leukotriene receptor E
  • Agonists: Leukotriene E4
Enzyme
(inhibitors)
5-LOXTooltip Arachidonate 5-lipoxygenase
  • FLAPTooltip Arachidonate 5-lipoxygenase-activating protein inhibitors: AM-103
  • AM-679
  • BAYx1005
  • MK-591
  • MK-886
12-LOXTooltip Arachidonate 12-lipoxygenase
15-LOXTooltip Arachidonate 15-lipoxygenase
LTA4HTooltip Leukotriene A4 hydrolase
LTB4HTooltip Leukotriene B4 ω-hydroxylase
  • 17-Octadecynoic acid
LTC4STooltip Leukotriene C4 synthase
LTC4HTooltip Leukotriene C4 hydrolase
LTD4Tooltip Leukotriene D4 hydrolase
Others
See also
Receptor/signaling modulators
Prostanoid signaling modulators
  • v
  • t
  • e
Calcium
VDCCsTooltip Voltage-dependent calcium channels
Blockers
Activators
Potassium
VGKCsTooltip Voltage-gated potassium channels
Blockers
Activators
IRKsTooltip Inwardly rectifying potassium channel
Blockers
Activators
  • GIRKTooltip G protein-coupled inwardly rectifying potassium channel-specific: ML-297 (VU0456810)
KCaTooltip Calcium-activated potassium channel
Blockers
  • BKCa-specific: Ethanol (alcohol)
  • GAL-021
Activators
K2PsTooltip Tandem pore domain potassium channel
Blockers
Activators
Sodium
VGSCsTooltip Voltage-gated sodium channels
Blockers
Activators
ENaCTooltip Epithelial sodium channel
Blockers
Activators
  • Solnatide
ASICsTooltip Acid-sensing ion channel
Blockers
Chloride
CaCCsTooltip Calcium-activated chloride channel
Blockers
Activators
CFTRTooltip Cystic fibrosis transmembrane conductance regulator
Blockers
Activators
Unsorted
Blockers
Others
TRPsTooltip Transient receptor potential channels
  • See here instead.
LGICsTooltip Ligand gated ion channels
  • See here instead.
See also: Receptor/signaling modulators • Transient receptor potential channel modulators